NO940261L - 5-membered heterocycles, process for the preparation thereof and drugs containing these compounds - Google Patents

5-membered heterocycles, process for the preparation thereof and drugs containing these compounds

Info

Publication number
NO940261L
NO940261L NO940261A NO940261A NO940261L NO 940261 L NO940261 L NO 940261L NO 940261 A NO940261 A NO 940261A NO 940261 A NO940261 A NO 940261A NO 940261 L NO940261 L NO 940261L
Authority
NO
Norway
Prior art keywords
compounds
preparation
membered heterocycles
drugs containing
salts
Prior art date
Application number
NO940261A
Other languages
Norwegian (no)
Other versions
NO940261D0 (en
Inventor
Gunter Linz
Frank Himmelsbach
Volkhard Austel
Helmut Pieper
Thomas Muller
Hans Weisenberger
Brian Guth
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of NO940261D0 publication Critical patent/NO940261D0/en
Publication of NO940261L publication Critical patent/NO940261L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Denne oppfinnelse vedrører 5-leddede heterocykler med den generelle formel. hvori. Xtil Xer definert som i krav 1, deres tautomerer, deres stereoisomerer innbefattet deres blandinger og deres salter, særlig deres fysiologisk aksepterbare salter med uorganiske eller organiske syrer eller baser, som har verdifulle farma-kologiske egenskaper, fortrinnsvis aggregeringshemmende virk-ninger, legemidler som inneholder forbindelsene og fremgangs-måter for deres fremstilling.This invention relates to 5-membered heterocycles of the general formula. where. Xtil Xer as defined in claim 1, their tautomers, their stereoisomers including their mixtures and their salts, in particular their physiologically acceptable salts with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably anti-aggregation effects, drugs containing the compounds and methods of their preparation.

NO940261A 1993-01-26 1994-01-25 5-membered heterocycles, process for the preparation thereof and drugs containing these compounds NO940261L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4302051A DE4302051A1 (en) 1993-01-26 1993-01-26 5-membered heterocycles, process for their preparation and medicaments containing these compounds

Publications (2)

Publication Number Publication Date
NO940261D0 NO940261D0 (en) 1994-01-25
NO940261L true NO940261L (en) 1994-07-27

Family

ID=6478937

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940261A NO940261L (en) 1993-01-26 1994-01-25 5-membered heterocycles, process for the preparation thereof and drugs containing these compounds

Country Status (18)

Country Link
EP (1) EP0608858A1 (en)
JP (1) JPH072851A (en)
KR (1) KR940018382A (en)
CN (1) CN1097753A (en)
AU (1) AU5398494A (en)
BG (1) BG98409A (en)
CA (1) CA2114178A1 (en)
CZ (1) CZ18194A3 (en)
DE (1) DE4302051A1 (en)
FI (1) FI940378A (en)
HU (1) HU9400217D0 (en)
IL (1) IL108436A0 (en)
NO (1) NO940261L (en)
NZ (1) NZ250762A (en)
PL (1) PL302018A1 (en)
RU (1) RU94002482A (en)
SK (1) SK8394A3 (en)
ZA (1) ZA94495B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
CA2229617A1 (en) * 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation
US6083986A (en) * 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
PL345247A1 (en) 1998-07-01 2001-12-03 Takeda Chemical Industries Ltd Retinoid-associated receptor regulators
WO2000047188A1 (en) * 1999-02-11 2000-08-17 Emisphere Technologies, Inc. Oxadiazole compounds and compositions for delivering active agents
US7084279B1 (en) 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
EP1240147A1 (en) 1999-12-21 2002-09-18 Icagen, Inc. Potassium channel inhibitors
AU2000223275A1 (en) * 2000-02-08 2001-08-20 Yamanouchi Pharmaceutical Co..Ltd. Novel triazole derivatives
WO2001087855A1 (en) * 2000-05-19 2001-11-22 Yamanouchi Pharmaceutical Co., Ltd. Triazole derivatives
US6566380B2 (en) 2000-07-25 2003-05-20 Icagen, Inc. Potassium channel inhibitors
US6620849B2 (en) 2000-07-26 2003-09-16 Icafen, Inc. Potassium channel inhibitors
US6849634B2 (en) 2000-12-21 2005-02-01 Icagen Potassium channel inhibitors
US7223791B2 (en) * 2001-06-26 2007-05-29 Takeda Pharmaceutical Company Limited Function regulator for retinoid relative receptor
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
AU2003218028A1 (en) 2002-03-08 2003-09-22 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
JP4926402B2 (en) 2002-11-27 2012-05-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 1,2,3-Triazoleamide derivatives as cytokine inhibitors
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
BRPI0409686A (en) 2003-04-24 2006-07-04 Incyte Corp aza spiro alkane derivatives as metalloprotease inhibitors
EP2316827B1 (en) 2003-07-30 2016-01-27 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
ES2360292T3 (en) 2003-12-03 2011-06-02 Boehringer Ingelheim Pharmaceuticals Inc. 1,2,3-TRIAZOL AMIDA DERIVATIVES AS INHIBITORS OF CYTOKIN PRODUCTION.
PT1725544E (en) 2004-03-09 2009-07-02 Boehringer Ingelheim Pharma 3-[4-heterocyclyl-1,2,3-triazol-1-yl]-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases
WO2005108387A2 (en) 2004-05-03 2005-11-17 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
US7485657B2 (en) 2004-05-12 2009-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
EP2269610A3 (en) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580845A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
MX2007003318A (en) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes.
BRPI0515488A (en) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc heterocyclic derivatives and their use as therapeutic agents
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CN101084207A (en) 2004-09-20 2007-12-05 泽农医药公司 Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007003327A (en) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase.
US7531560B2 (en) 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
JP2009513563A (en) 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
TW200811164A (en) * 2006-05-12 2008-03-01 Jerini Ag New heterocyclic compounds for the inhibition of integrins and use thereof
US7910108B2 (en) 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
RU2009110254A (en) 2006-08-24 2010-09-27 Новартис АГ (CH) 2- (PYRAZIN-2-IL) THIAZOLE DERIVATIVES AND 2- (1H-PYRAZOL-3-IL) THYRAZOL AND COMPOUNDS CONNECTED WITH IT AS STEAROIL-SOA INHIBERATOUS AND SMOKE
PL2090570T3 (en) 2006-09-05 2012-03-30 Kyowa Hakko Kirin Co Ltd Imidazole derivative
CA2685266C (en) 2007-04-27 2014-01-28 Purdue Pharma L.P. Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
CA2801074A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
EP2723732B1 (en) 2011-06-22 2017-01-18 Purdue Pharma LP Trpv1 antagonists including dihydroxy substituent and uses thereof
US9593106B2 (en) 2013-02-07 2017-03-14 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
GB201810071D0 (en) 2018-06-19 2018-08-08 Univ Oslo Hf Compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98757A (en) * 1990-07-18 1997-01-10 Novo Nordisk As Piperidine derivatives their preparation and pharmaceutical compositions containing them
DE4124942A1 (en) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING SUCH COMPOUNDS

Also Published As

Publication number Publication date
CA2114178A1 (en) 1994-07-27
CZ18194A3 (en) 1994-11-16
DE4302051A1 (en) 1994-07-28
NO940261D0 (en) 1994-01-25
CN1097753A (en) 1995-01-25
EP0608858A1 (en) 1994-08-03
BG98409A (en) 1994-09-30
HU9400217D0 (en) 1994-05-30
ZA94495B (en) 1995-07-25
AU5398494A (en) 1994-08-04
IL108436A0 (en) 1994-04-12
PL302018A1 (en) 1994-08-08
FI940378A (en) 1994-07-27
NZ250762A (en) 1995-08-28
KR940018382A (en) 1994-08-16
RU94002482A (en) 1996-08-27
SK8394A3 (en) 1995-02-08
FI940378A0 (en) 1994-01-26
JPH072851A (en) 1995-01-06

Similar Documents

Publication Publication Date Title
NO940261L (en) 5-membered heterocycles, process for the preparation thereof and drugs containing these compounds
NO934501L (en) Carboxylic acid derivatives, drugs containing these compounds, and process for their preparation
NO972881L (en) Piperazine derivatives, drugs containing them, their use and methods for their preparation
NO933248L (en) Cyclic urea derivatives, drugs containing these compounds, and process for their preparation
NO922940L (en) FIVE-JOINT HETEROCYCLIC COMPOUNDS, PROCEDURES FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM
NO923466L (en) Heterocyclic Compounds with 5 Sections, PROCEDURE PREPARATION, AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS
NO984084L (en) 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and method of preparation thereof
NO932120L (en) Biphenyl derivatives, drugs containing them, and methods for their preparation
NO924027L (en) Heterobia Age Derivatives, Drugs Containing These Compounds, and Procedures for Their Preparation
NO20051100L (en) Pyrazole compositions useful as GSK-3 inhibitors
MX9803954A (en) Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them.
NZ335396A (en) Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors
NO20092860L (en) 2, 6 dioxopiperidine and pharmaceutical compositions containing them
NO964700L (en) Novel amino acid derivatives, processes for their preparation and pharmaceutical compositions containing these compounds
NO20023161L (en) Substituted piperidines, drugs containing these compounds and processes for their preparation
DK5389A (en) SUBSTITUTED PYRROLES, PYRAZOLES AND TRIAZOLES, PROCEDURES FOR THEIR PREPARATION AND THEIR USE AS ANGIOTENSIN II ANTAGONISTS
DK0567966T3 (en) Cyclic amino derivatives, processes for their preparation, and drugs containing these compounds
PH27592A (en) Imidazolyl-alkenoic acids and its method of use
NO941677D0 (en) Tetrazole derivatives of bile acids, methods of preparation and their use as a drug
BR0212586A (en) Composition, use of a combination of ipratropium or a salt thereof and xylometazoline or a salt thereof, and methods for the treatment of a condition selected from the group consisting of symptoms associated with the common cold and symptoms associated with rhinitis and to stabilize an aqueous solution of ipratropium or a salt thereof and xylometazoline or a salt thereof
NO940524L (en)
YU30902A (en) Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof
NO931527L (en) CYCLIC IMINO DERIVATIVES, MEDICINAL PREPARATIONS CONTAINING THESE, AND PROCEDURE FOR THEIR PREPARATION
NO952205L (en) Heterocyclic carbamates, process for their preparation and medicaments
BR0211030A (en) Pyrrolidine oxadiazole derivative, use of a pyrrolidine oxadiazole derivative, pharmaceutical composition containing at least one pyrrolidine oxadiazole derivative, method for preparing a pyrrolidine oxadiazole compound